The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience

Mitchell D Creinin, Andrew M. Kaunitz, Philip D. Darney, Lisa Schwartz, Tonja Hampton, Keith Gordon, Hans Rekers

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: The objective was to monitor the effectiveness of the etonogestrel implant clinical training program through a voluntary active monitoring program (AMP). Study design: US health care providers underwent mandatory training by the manufacturer on etonogestrel implant insertion, localization and removal. After training, health care providers could enroll in a voluntary AMP to provide outcome data to meet a postmarketing commitment of the manufacturer with the US Food and Drug Administration (FDA). Those who volunteered completed and faxed forms to the manufacturer after implant insertion and removal detailing the procedure and device-related outcomes, including insertion-, localization- or removal-associated events. Experts reviewed outcome data quarterly, which the Sponsor then reported to the FDA. Results: Among 42,337 health care providers completing the training program, 4294 (10.1%) volunteered to participate in the AMP. The 26,198 forms submitted over 6.4 years included more insertion (n=20,497) forms than removal forms (n=5701). The volunteers reported 646 events on 566 (2.2%) forms related to insertion (n=197), localization (n=34), removal (n=357) and "other" (n=58). Clinically important events included noninsertion (n=4), serum etonogestrel positive but implant not found (n=1), and possible nerve (n=66) or vascular (n=5) injury. The reports did not include any insertion-, localization- or removal-associated hospitalizations. Eight (0.14%) removal reports described referral for surgical implant removal. Conclusion: Events related to insertion, localization or removal of the etonogestrel implant are uncommon among US providers who received mandatory training in the use of the implant. Implications: This report presents results from the first mandatory US contraceptive training program. Health care providers volunteered to report information about etonogestrel implant insertion, localization and removal. Although the data do not demonstrate whether a mandatory program improves outcomes, they elucidate the utility and real-life experience that clinical training programs can provide.

Original languageEnglish (US)
JournalContraception
DOIs
StateAccepted/In press - Feb 24 2016

Fingerprint

Health Personnel
Education
United States Food and Drug Administration
Mandatory Programs
Contraceptive Agents
Blood Vessels
Volunteers
Hospitalization
Referral and Consultation
etonogestrel
Equipment and Supplies
Wounds and Injuries
Serum

Keywords

  • Contraceptive implant
  • Etonogestrel
  • Monitoring
  • Training

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

The US etonogestrel implant mandatory clinical training and active monitoring programs : 6-year experience. / Creinin, Mitchell D; Kaunitz, Andrew M.; Darney, Philip D.; Schwartz, Lisa; Hampton, Tonja; Gordon, Keith; Rekers, Hans.

In: Contraception, 24.02.2016.

Research output: Contribution to journalArticle

Creinin, Mitchell D ; Kaunitz, Andrew M. ; Darney, Philip D. ; Schwartz, Lisa ; Hampton, Tonja ; Gordon, Keith ; Rekers, Hans. / The US etonogestrel implant mandatory clinical training and active monitoring programs : 6-year experience. In: Contraception. 2016.
@article{89ef87656dc949aab4ebd3742e59b46d,
title = "The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience",
abstract = "Objective: The objective was to monitor the effectiveness of the etonogestrel implant clinical training program through a voluntary active monitoring program (AMP). Study design: US health care providers underwent mandatory training by the manufacturer on etonogestrel implant insertion, localization and removal. After training, health care providers could enroll in a voluntary AMP to provide outcome data to meet a postmarketing commitment of the manufacturer with the US Food and Drug Administration (FDA). Those who volunteered completed and faxed forms to the manufacturer after implant insertion and removal detailing the procedure and device-related outcomes, including insertion-, localization- or removal-associated events. Experts reviewed outcome data quarterly, which the Sponsor then reported to the FDA. Results: Among 42,337 health care providers completing the training program, 4294 (10.1{\%}) volunteered to participate in the AMP. The 26,198 forms submitted over 6.4 years included more insertion (n=20,497) forms than removal forms (n=5701). The volunteers reported 646 events on 566 (2.2{\%}) forms related to insertion (n=197), localization (n=34), removal (n=357) and {"}other{"} (n=58). Clinically important events included noninsertion (n=4), serum etonogestrel positive but implant not found (n=1), and possible nerve (n=66) or vascular (n=5) injury. The reports did not include any insertion-, localization- or removal-associated hospitalizations. Eight (0.14{\%}) removal reports described referral for surgical implant removal. Conclusion: Events related to insertion, localization or removal of the etonogestrel implant are uncommon among US providers who received mandatory training in the use of the implant. Implications: This report presents results from the first mandatory US contraceptive training program. Health care providers volunteered to report information about etonogestrel implant insertion, localization and removal. Although the data do not demonstrate whether a mandatory program improves outcomes, they elucidate the utility and real-life experience that clinical training programs can provide.",
keywords = "Contraceptive implant, Etonogestrel, Monitoring, Training",
author = "Creinin, {Mitchell D} and Kaunitz, {Andrew M.} and Darney, {Philip D.} and Lisa Schwartz and Tonja Hampton and Keith Gordon and Hans Rekers",
year = "2016",
month = "2",
day = "24",
doi = "10.1016/j.contraception.2016.07.012",
language = "English (US)",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - The US etonogestrel implant mandatory clinical training and active monitoring programs

T2 - 6-year experience

AU - Creinin, Mitchell D

AU - Kaunitz, Andrew M.

AU - Darney, Philip D.

AU - Schwartz, Lisa

AU - Hampton, Tonja

AU - Gordon, Keith

AU - Rekers, Hans

PY - 2016/2/24

Y1 - 2016/2/24

N2 - Objective: The objective was to monitor the effectiveness of the etonogestrel implant clinical training program through a voluntary active monitoring program (AMP). Study design: US health care providers underwent mandatory training by the manufacturer on etonogestrel implant insertion, localization and removal. After training, health care providers could enroll in a voluntary AMP to provide outcome data to meet a postmarketing commitment of the manufacturer with the US Food and Drug Administration (FDA). Those who volunteered completed and faxed forms to the manufacturer after implant insertion and removal detailing the procedure and device-related outcomes, including insertion-, localization- or removal-associated events. Experts reviewed outcome data quarterly, which the Sponsor then reported to the FDA. Results: Among 42,337 health care providers completing the training program, 4294 (10.1%) volunteered to participate in the AMP. The 26,198 forms submitted over 6.4 years included more insertion (n=20,497) forms than removal forms (n=5701). The volunteers reported 646 events on 566 (2.2%) forms related to insertion (n=197), localization (n=34), removal (n=357) and "other" (n=58). Clinically important events included noninsertion (n=4), serum etonogestrel positive but implant not found (n=1), and possible nerve (n=66) or vascular (n=5) injury. The reports did not include any insertion-, localization- or removal-associated hospitalizations. Eight (0.14%) removal reports described referral for surgical implant removal. Conclusion: Events related to insertion, localization or removal of the etonogestrel implant are uncommon among US providers who received mandatory training in the use of the implant. Implications: This report presents results from the first mandatory US contraceptive training program. Health care providers volunteered to report information about etonogestrel implant insertion, localization and removal. Although the data do not demonstrate whether a mandatory program improves outcomes, they elucidate the utility and real-life experience that clinical training programs can provide.

AB - Objective: The objective was to monitor the effectiveness of the etonogestrel implant clinical training program through a voluntary active monitoring program (AMP). Study design: US health care providers underwent mandatory training by the manufacturer on etonogestrel implant insertion, localization and removal. After training, health care providers could enroll in a voluntary AMP to provide outcome data to meet a postmarketing commitment of the manufacturer with the US Food and Drug Administration (FDA). Those who volunteered completed and faxed forms to the manufacturer after implant insertion and removal detailing the procedure and device-related outcomes, including insertion-, localization- or removal-associated events. Experts reviewed outcome data quarterly, which the Sponsor then reported to the FDA. Results: Among 42,337 health care providers completing the training program, 4294 (10.1%) volunteered to participate in the AMP. The 26,198 forms submitted over 6.4 years included more insertion (n=20,497) forms than removal forms (n=5701). The volunteers reported 646 events on 566 (2.2%) forms related to insertion (n=197), localization (n=34), removal (n=357) and "other" (n=58). Clinically important events included noninsertion (n=4), serum etonogestrel positive but implant not found (n=1), and possible nerve (n=66) or vascular (n=5) injury. The reports did not include any insertion-, localization- or removal-associated hospitalizations. Eight (0.14%) removal reports described referral for surgical implant removal. Conclusion: Events related to insertion, localization or removal of the etonogestrel implant are uncommon among US providers who received mandatory training in the use of the implant. Implications: This report presents results from the first mandatory US contraceptive training program. Health care providers volunteered to report information about etonogestrel implant insertion, localization and removal. Although the data do not demonstrate whether a mandatory program improves outcomes, they elucidate the utility and real-life experience that clinical training programs can provide.

KW - Contraceptive implant

KW - Etonogestrel

KW - Monitoring

KW - Training

UR - http://www.scopus.com/inward/record.url?scp=84979763365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979763365&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2016.07.012

DO - 10.1016/j.contraception.2016.07.012

M3 - Article

C2 - 27452317

AN - SCOPUS:84979763365

JO - Contraception

JF - Contraception

SN - 0010-7824

ER -